Ser39

Site Information
ttstrtysLGsALrP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 451766

In vivo Characterization
Methods used to characterize site in vivo:	2D analysis ( 70 ) , [32P] bio-synthetic labeling ( 70 , 73 ) , immunoassay ( 1 ) , immunoprecipitation ( 8 ) , mass spectrometry ( 6 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 21 , 22 , 23 , 24 , 26 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 73 ) , mass spectrometry (in vitro) ( 36 ) , mutation of modification site ( 1 , 8 , 11 , 36 , 59 , 73 ) , peptide sequencing ( 73 ) , phospho-antibody ( 1 , 3 , 4 , 5 , 7 , 12 , 20 , 27 , 36 , 59 , 72 ) , phosphopeptide mapping ( 73 ) , western blotting ( 1 , 3 , 4 , 5 , 7 , 8 , 20 , 36 , 59 )
Disease tissue studied:	brain cancer ( 20 ) , glioblastoma ( 20 ) , glioma ( 20 ) , breast cancer ( 8 , 12 , 22 , 27 ) , HER2 positive breast cancer ( 9 ) , luminal A breast cancer ( 9 ) , luminal B breast cancer ( 9 ) , breast cancer, surrounding tissue ( 9 ) , breast cancer, triple negative ( 9 , 12 ) , cervical cancer ( 51 ) , cervical adenocarcinoma ( 51 ) , gastric cancer ( 34 ) , gastric carcinoma ( 34 ) , leukemia ( 56 , 57 , 58 , 65 , 66 , 67 , 68 ) , acute myelogenous leukemia ( 56 , 57 , 58 , 65 , 66 , 67 , 68 ) , liver cancer ( 3 , 7 ) , hepatocellular carcinoma ( 3 , 7 ) , liver cancer, surrounding tissue ( 40 ) , lung cancer ( 17 , 22 , 27 , 38 , 45 , 46 , 47 , 49 , 50 ) , non-small cell lung cancer ( 22 , 45 , 46 , 47 , 49 , 50 ) , non-small cell lung adenocarcinoma ( 17 ) , neuroblastoma ( 21 ) , pancreatic ductal adenocarcinoma ( 16 ) , prostate cancer ( 4 ) , melanoma skin cancer ( 13 , 41 , 42 , 61 ) , leiomyosarcoma ( 36 ) , DKD ( 1 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 16 ) , 293 (epithelial) [AT1 (human), transfection] ( 39 ) , 786-O (renal) [VHL (human), transfection] ( 10 ) , 786-O (renal) ( 10 ) , A549 (pulmonary) ( 27 ) , BHK-21 (fibroblast) ( 73 ) , BJ (fibroblast) ( 27 ) , bone marrow ( 56 , 57 , 58 , 65 , 66 , 67 , 68 ) , breast ( 9 ) , BT-20 (breast cell) ( 22 ) , BT-549 (breast cell) ( 22 ) , Calu 6 (pulmonary) ( 22 ) , CL1-0 (pulmonary) ( 38 ) , CL1-1 (pulmonary) ( 38 ) , CL1-2 (pulmonary) ( 38 ) , CL1-5 (pulmonary) ( 38 ) , DU 145 (prostate cell) ( 4 ) , endothelial-aorta ( 23 ) , fibroblast-skin ( 71 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 24 ) , Flp-In T-Rex-293 (epithelial) ( 24 ) , H2009 (pulmonary) ( 22 ) , H2077 (pulmonary) ( 22 ) , H2887 (pulmonary) ( 22 ) , H322M (pulmonary) ( 22 ) , HCC1359 (pulmonary) ( 22 ) , HCC2279 (pulmonary) ( 22 ) , HCC366 (pulmonary) ( 22 ) , HCC4006 (pulmonary) ( 22 ) , HCC78 (pulmonary) ( 22 ) , HCC827 (pulmonary) ( 22 ) , HEK293T (epithelial) ( 69 ) , HeLa (cervical) ( 5 , 14 , 19 , 28 , 60 , 63 , 64 , 70 ) , HeLa S3 (cervical) [PLK1 (human), knockdown, Tet-inducible PLK1 siRNA] ( 37 ) , HeLa S3 (cervical) ( 37 , 51 , 55 ) , HK-2 (renal tubule cell) ( 1 ) , HOP62 (pulmonary) ( 22 ) , Hs 578T (breast cell) ( 8 ) , Jurkat (T lymphocyte) ( 18 , 26 , 29 , 30 , 31 , 32 , 33 , 35 , 43 , 44 , 52 , 53 , 54 , 62 ) , K562 (erythroid) ( 19 ) , LCLC-103H (pulmonary) ( 22 ) , leukocyte-blood ( 48 ) , liver ( 15 , 40 ) , LOU-NH91 (squamous) ( 22 ) , lung ( 17 , 45 , 46 , 47 , 49 , 50 ) , macrophage-bone marrow ( 59 ) , MCF-7 (breast cell) ( 8 , 27 ) , MDA-MB-231 (breast cell) ( 8 , 22 ) , MDA-MB-435S (breast cell) ( 12 ) , MDA-MB-468 (breast cell) ( 22 ) , MEF (fibroblast) ( 12 ) , MFH-M ( 36 ) , MFT-16 ( 11 ) , MHCC97H (hepatic) ( 3 , 7 ) , NB10 (neural crest) ( 21 ) , NCI-H1395 (pulmonary) ( 22 ) , NCI-H1568 (pulmonary) ( 22 ) , NCI-H157 (pulmonary) ( 22 ) , NCI-H1648 (pulmonary) ( 22 ) , NCI-H1666 (pulmonary) ( 22 ) , NCI-H2030 (pulmonary) ( 22 ) , NCI-H2172 (pulmonary) ( 22 ) , NCI-H322 (pulmonary) ( 22 ) , NCI-H460 (pulmonary) ( 22 ) , NCI-H520 (squamous) ( 22 ) , NCI-H647 (pulmonary) ( 22 ) , NPC (neural crest) ( 21 ) , PC3 (prostate cell) ( 4 ) , PC9 (pulmonary) ( 22 ) , SK-LMS-1 (muscle cell) ( 36 ) , skin ( 41 , 42 , 61 ) , stomach ( 34 ) , T47D (breast cell) ( 8 ) , U-251 MG (glial) ( 20 ) , Vero (epithelial) ( 72 ) , Vero E6-S ('epithelial, kidney') ( 6 ) , WM239A (melanocyte) ( 13 )

Upstream Regulation
Regulatory protein:	Rab7 (human) ( 5 ) , ROCK1 (human) ( 7 ) , ROCK2 (human) ( 7 )
Putative in vivo kinases:	Akt1 (human) ( 5 , 36 ) , PKCI (human) ( 4 ) , PKCZ (human) ( 4 )
Kinases, in vitro:	Akt1 (human) ( 36 ) , PAK1 (mouse) ( 74 ) , PKACA (human) ( 70 , 73 )
Treatments:	A-674563 ( 36 ) , angiotensin-(1-7) ( 23 ) , calyculin_A ( 72 , 73 ) , EGF ( 36 ) , GDC0068 ( 5 ) , IPA-3 ( 7 ) , LY294002 ( 36 ) , metastatic potential ( 38 ) , nocodazole ( 51 ) , NSC23766 ( 7 ) , rapamycin ( 36 ) , siRNA ( 4 ) , sphingosine_1-phosphate ( 12 ) , sphingosylphosphorylcholine ( 12 ) , TGF-beta ( 1 ) , withaferin_A ( 27 ) , Y27632 ( 28 )

Downstream Regulation
Effects of modification on Vimentin:	activity, induced ( 4 ) , molecular association, regulation ( 73 , 74 ) , phosphorylation ( 73 ) , protein degradation ( 8 ) , protein stabilization ( 36 )
Effects of modification on biological processes:	carcinogenesis, altered ( 36 ) , carcinogenesis, induced ( 4 ) , carcinogenesis, inhibited ( 8 ) , cell motility, altered ( 36 , 59 ) , cell motility, induced ( 4 ) , cytoskeletal reorganization ( 4 , 73 , 74 ) , transcription, altered ( 4 )
Inhibit interaction with:	Vimentin (hamster) ( 73 ) , Vimentin (human) ( 74 )

References
1	Wang D, et al. (2023) Phosphorylated vimentin at Ser72 is associated with epithelial-mesenchymal transition in lupus nephritis. Int J Rheum Dis 38078507 Curated Info
2	Kuburich NA, et al. (2023) Stabilizing vimentin phosphorylation inhibits stem-like cell properties and metastasis of hybrid epithelial/mesenchymal carcinomas. Cell Rep 42, 113470 37979166 Curated Info
3	Hu X, et al. (2023) Golgi-protein 73 facilitates vimentin polymerization in hepatocellular carcinoma. Int J Biol Sci 19, 3694-3708 37564210 Curated Info
4	Ratnayake WS, et al. (2021) Atypical PKCs activate Vimentin to facilitate prostate cancer cell motility and invasion. Cell Adh Migr 15, 37-57 33525953 Curated Info
5	Romano R, et al. (2021) RAB7A Regulates Vimentin Phosphorylation through AKT and PAK. Cancers (Basel) 13 34066419 Curated Info
6	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
7	Zhang JG, et al. (2020) Hypoxic induction of vasculogenic mimicry in hepatocellular carcinoma: role of HIF-1 ¿¿, RhoA/ROCK and Rac1/PAK signaling. BMC Cancer 31931758 Curated Info
8	Pang K, et al. (2019) RNF208, an estrogen-inducible E3 ligase, targets soluble Vimentin to suppress metastasis in triple-negative breast cancers. Nat Commun 10, 5805 31862882 Curated Info
9	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
10	Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72 26506913 Curated Info
11	Matveeva EA, Venkova LS, Chernoivanenko IS, Minin AA (2015) Vimentin is involved in regulation of mitochondrial motility and membrane potential by Rac1. Biol Open 4, 1290-7 26369929 Curated Info
12	Hyder CL, et al. (2015) Sphingolipids inhibit vimentin-dependent cell migration. J Cell Sci 128, 2057-69 25908861 Curated Info
13	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
14	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
15	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
16	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
17	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
18	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
19	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
20	Haolong C, et al. (2013) Enterovirus 71 VP1 activates calmodulin-dependent protein kinase II and results in the rearrangement of vimentin in human astrocyte cells. PLoS One 8, e73900 24073199 Curated Info
21	DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513 24349301 Curated Info
22	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
23	Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81 22497526 Curated Info
24	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
25	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
26	Mulhern D (2012) CST Curation Set: 13339; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
27	Grin B, et al. (2012) Withaferin a alters intermediate filament organization, cell shape and behavior. PLoS One 7, e39065 22720028 Curated Info
28	Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ζ affinity chromatography. Cell Struct Funct 37, 39-48 22251793 Curated Info
29	Mulhern D (2011) CST Curation Set: 13072; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631 Curated Info
30	Mulhern D (2011) CST Curation Set: 13031; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Curated Info
31	Zhou J (2011) CST Curation Set: 12763; Year: 2011; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Curated Info
32	Zhou J (2011) CST Curation Set: 12029; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821 Curated Info
33	Zhou J (2011) CST Curation Set: 12030; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821 Curated Info
34	Rikova K (2011) CST Curation Set: 12177; Year: 2011; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
35	Guo A (2011) CST Curation Set: 12063; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Curated Info
36	Zhu QS, et al. (2011) Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 30, 457-70 20856200 Curated Info
37	Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457 20860994 Curated Info
38	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
39	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
40	Tucker M (2010) CST Curation Set: 9837; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
41	Tucker M (2010) CST Curation Set: 9784; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
42	Tucker M (2010) CST Curation Set: 9786; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
43	Possemato A (2010) CST Curation Set: 9722; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R) Curated Info
44	Possemato A (2010) CST Curation Set: 9724; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
45	Rikova K (2010) CST Curation Set: 9456; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
46	Rikova K (2010) CST Curation Set: 9457; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
47	Rikova K (2010) CST Curation Set: 9471; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
48	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
49	Rikova K (2010) CST Curation Set: 9013; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
50	Rikova K (2010) CST Curation Set: 9014; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
51	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
52	Moritz A (2009) CST Curation Set: 8723; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
53	Moritz A (2009) CST Curation Set: 8724; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
54	Possemato A (2009) CST Curation Set: 8591; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
55	Malik R, et al. (2009) Quantitative analysis of the human spindle phosphoproteome at distinct mitotic stages. J Proteome Res 8, 4553-63 19691289 Curated Info
56	Gu T (2009) CST Curation Set: 7674; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
57	Gu T (2009) CST Curation Set: 7673; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
58	Gu T (2009) CST Curation Set: 7670; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
59	Barberis L, et al. (2009) Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin. Eur J Immunol 39, 1136-46 19291697 Curated Info
60	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
61	Tucker M (2008) CST Curation Set: 5371; Year: 2008; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info
62	Possemato A (2008) CST Curation Set: 5196; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
63	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
64	Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51 18220336 Curated Info
65	Gu T (2007) CST Curation Set: 2608; Year: 2007; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983 Curated Info
66	Gu T (2007) CST Curation Set: 2582; Year: 2007; Biosample/Treatment: tissue, bone marrow/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
67	Gu T (2007) CST Curation Set: 2583; Year: 2007; Biosample/Treatment: tissue, bone marrow/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
68	Gu T (2007) CST Curation Set: 2584; Year: 2007; Biosample/Treatment: tissue, bone marrow/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpTPAntibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK Substrates (PXTP) (46G11) Rabbit mAb Cat#: 4391, PTMScan(R) Phospho-MAPK Substrate Motif (PXpTP) Immunoaffinity Beads Cat#: 1983 Curated Info
69	Molina H, et al. (2007) Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199-204 17287340 Curated Info
70	Kochin V, Imanishi SY, Eriksson JE (2006) Fast track to a phosphoprotein sketch - MALDI-TOF characterization of TLC-based tryptic phosphopeptide maps at femtomolar detection sensitivity. Proteomics 6, 5676-82 17024653 Curated Info
71	Yang F, et al. (2006) Phosphoproteome profiling of human skin fibroblast cells in response to low- and high-dose irradiation. J Proteome Res 5, 1252-60 16674116 Curated Info
72	Stefanovic S, et al. (2005) Vimentin rearrangement during African swine fever virus infection involves retrograde transport along microtubules and phosphorylation of vimentin by calcium calmodulin kinase II. J Virol 79, 11766-75 16140754 Curated Info
73	Eriksson JE, et al. (2004) Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J Cell Sci 117, 919-32 14762106 Curated Info
74	Goto H, et al. (2002) Phosphorylation and reorganization of vimentin by p21-activated kinase (PAK). Genes Cells 7, 91-7 11895474 Curated Info